Vaginal mAB Delivery Systems

阴道 mAB 输送系统

• 批准号: 8515321
• 负责人: Thomas Ray Moench
• 金额: $ 7.85万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8515321
• 关键词: Antibodies; Categories; Cervix Uteri; Data; Development; Devices; Effectiveness; Failure; HIV; Human; Immune system; Infection; Instruction; Methods; Monoclonal Antibodies; System; Tenofovir; Vagina; Vaginal Diaphragm; Vaginal Gel; Vaginal Ring; base; microbicide; novel; prevent; small molecule; vaginal microbicide

The recent successful trial of tenofovir vaginal gel provides important proof of concept indicating that a vaginal microbicide can prevent HIV. However, the limited protection observed (39% overall), argues for the development of additional microbicide agents and methods to deliver them. This IPCP application will develop a monoclonal antibody (Mab) based microbicide, distinct from the small molecule antiretrovirals that dominate the current microbicide pipeline. Mabs show promise in providing safe, potent, and specific, yet broad-spectrum microbicide action. Project 4 will attempt to enhance Mab effectiveness by its focus on the means of Mab delivery. Limitations on microbicide effectiveness can be divided into two categories: first, intrinsic failure of the method to provide protection when used (

替诺福韦阴道凝胶的最近成功试验提供了重要的概念证明，表明阴道杀菌剂可以预防HIV。但是，有限的保护观察到（总体上为39％），认为开发了额外的菌心剂和交付它们的方法。该IPCP应用将开发基于单克隆抗体（MAB）的菌心，该杀菌剂与主导当前杀菌剂管道的小分子抗逆转录病毒不同。 mabs在提供安全，有效，特定但广谱菌心的作用方面表现出了希望。项目4将尝试通过关注MAB交付方式来增强MAB的有效性。对杀菌剂有效性的局限性可以分为两类：首先，该方法在使用时提供保护的固有故障（